Evaluation of NTP42, a novel thromboxane receptor antagonist, in a first-in-human phase I clinical trial

• मुख्य लेखकों: Helen M. Reid (लेखक), Mark Maginn (लेखक), C. Michael Perkins (लेखक), Eamon P. Mulvaney (लेखक), Malcolm Boyce (लेखक), Takahiro Yamamoto (लेखक), B. Therese Kinsella (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Frontiers Media S.A., 2023-12-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Background: The thromboxane receptor (TP) antagonist NTP42 is in clinical development for treatment of cardiopulmonary diseases, such as pulmonary arterial hypertension. In this randomized, placebo-controlled Phase I clinical trial, NTP42, administered as the oral formulation NTP42:KVA4, was evaluat...